logo UCSF Benioff Children's Hospital Oakland
Hematology/Oncology Department
Research Studies Open for Enrollment
Date: 10/30/2020
Title ID/Protocol NCT/Phase Sponsor P.I. Contact
Oncology, Solid Tumors
Effects of Modern Chemotherapy Regimens on Spermatogenesis and Steroidogenesis in Adolescent and Young Adult (AYA) Survivors of OsteosarcomaALTE16C1 NCT03206450
N/A
Children's Oncology Group (COG)Carla Golden, MDDiane Olszewski (510-428-3885 x 3246)
LEAHRN (Late Effects After High-Risk Neuroblastoma) StudyALTE15N2 NCT03057626
N/A
Children's Oncology Group (COG)Carla Golden, MDDiane Olszewski (510-428-3885 x 3246)
Neuroblastoma Classification Biology StudiesANBL00B1 NCT00904241
Children's Oncology Group (COG)Carla Golden, MDDiane Olszewski (510-428-3885 x 3246)
Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)AHEP1531 NCT03533582
Phase 3
Children's Oncology Group (COG)Carla Golden, MDDiane Olszewski (510-428-3885 x 3246)
Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell TumorsAGCT1531 NCT03067181
Phase 3
Children's Oncology Group (COG)Carla Golden, MDDiane Olszewski (510-428-3885 x 3246)
Randomized Phase 3 Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alt. w. Vincristine/Irinotecan (VI) Vs VAC/VI Plus Temsirolimus (TORI, Torisel) in Patients with Intermediate Risk (IR) Rhabdomyosarcoma (RMS)ARST1431 NCT02567435
Phase 3
Children's Oncology Group (COG)Carla Golden, MDDiane Olszewski (510-428-3885 x 3246)
Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk NeuroblastomaANBL1232 NCT02176967
Phase 3
Children's Oncology Group (COG)Carla Golden, MDDiane Olszewski (510-428-3885 x 3246)
NEURO-ONCOLOGY
Genomic Analysis in Pediatric MalignanciesGenomics N/A
N/ATabitha Cooney, MDTabitha Cooney, MD
Prospective multi-institutional study to assess the risk of radiation induced vasculopathy and stroke as well as stroke recurrence in children with cancer who received radiation therapy to the neck and/or brainRadART-Pro N/A
LaRoche FamilyJoseph Torkildson, MDJoseph Torkildson, MD
Oncology, Neuro-Oncology
Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma PatientsACNS1422 NCT02724579
Phase 2
Children's Oncology Group (COG)Carla Golden, MDDiane Olszewski (510-428-3885 x 3246)
Oncology, Neuro-Oncology, Solid Tumors
Clinical/Molecular Risk-Tailored Intensive, Compressed Induction Chemotherapy Followed by Consolidation Randomization To Single-Cycle or 3 Tandem Cycles of Marrow-Ablative Chemo with Hematopoietic Progenitor Cell RescueHead-Start-4 NCT02875314
Phase 4
Next Consortium, Nationwide Children'sCaroline Hastings, MDEffie Bourgin
GENERAL HEMATOLOGY
Randomized, open-label, active controlled, safety and extrapolated efficacy study in pediatric subjects requiring anticoagulation for treatment of a venous thromboembolic eventApixaban NCT02464969
Phase 4
PfizerTiti Singer, MDSheila Contapay-Tabilin, RN (510-428-3885 x4754)

UCSF Benioff Children's Hospital Oakland • 747 52nd Street, Oakland, California 94609 • Phone: (510) 428-3000